Emergent BioSolutions Inc. — Director's Dealing 2020

Nov 13, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2020-11-09

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-09	Common Stock	M	20000	$26.45	Acquired	1143988	Direct
2020-11-09	Common Stock	S	20000	$95.26	Disposed	1123988	Direct
2020-11-10	Common Stock	M	19391	$26.45	Acquired	1143379	Direct
2020-11-10	Common Stock	S	19391	$88.21	Disposed	1123988	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-09	Stock Options (Right to Buy)	$26.45	M	20000	Disposed	2022-03-09	Common Stock (20000)	Direct
2020-11-10	Stock Options (Right to Buy)	$26.45	M	19391	Disposed	2022-03-09	Common Stock (19391)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2140463	Indirect
Common Stock	1524155	Indirect

Footnotes

F1: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.85 to $98.49. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.69 to $90.00. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Intervac, L.L.C. ("Intervac") is the direct owner of 2,140,463 shares of the Issuer's common stock. The Reporting Person serves as the managing member of Intervac and the Reporting Person or his wife serve as the trustee of each of the members of Intervac. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.

F5: The Reporting Person, individually, and the Reporting Person and his wife, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C., which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.

F6: The options vested in three equal installments on March 9 2016, March 9, 2017 and March 9, 2018.